AANPCB Board Prep/Evaluate
๐Ÿ“Š

Evaluate

Treatment response monitoring, plan modification, outcome measurement, medication adjustments, and quality improvement.

163 questions ยท AANPCB: 20% of exam
What the AANPCB tests in Evaluateโ–ถ

The Evaluate domain accounts for 20% of scored questions on the AANPCB PMHNP-C exam. It tests whether you can assess the effectiveness of a treatment plan and modify it based on patient outcomes โ€” the clinical follow-up and adjustment process.

Questions in this domain typically present a patient already on treatment: partial response to an antidepressant after 6 weeks, new-onset side effects from an antipsychotic, treatment failure after adequate trial. The correct answer requires determining whether to continue, augment, switch, add psychotherapy, change level of care, or reconsider the diagnosis.

The Evaluate domain also covers therapeutic drug monitoring (lithium levels, clozapine ANC, valproate levels), recognizing medication toxicity, managing discontinuation syndromes, and quality improvement in clinical practice. These questions test the longitudinal management that happens after the initial treatment plan is established.

Practice Evaluate Questions

Build a custom quiz and track your performance across all four AANPCB process domains. Free account required.

Build a Quiz

All 163 questions

1.
Lithium Therapeutic Monitoring and Toxicity
intermediatelithiumtoxicityrenal function
โ†’
2.
MAOI Dietary Restrictions and Hypertensive Crisis
intermediateMAOItyraminehypertensive crisis
โ†’
3.
Antipsychotic Metabolic Monitoring Guidelines
beginnermetabolic monitoringolanzapineantipsychotic
โ†’
4.
PHQ-9 Scoring and Clinical Interpretation
beginnerPHQ-9measurement-based caretreatment response
โ†’
5.
Therapeutic Alliance Rupture Repair
advancedtherapeutic alliancerupture repairSafran and Muran
โ†’
6.
Pharmacogenomics: CYP2D6 Poor Metabolizer Clinical Implications
advancedpharmacogenomicsCYP2D6poor metabolizer
โ†’
7.
Antipsychotic-Induced Akathisia Recognition and Management
intermediateakathisiaextrapyramidal symptomsaripiprazole
โ†’
8.
Gabapentin Misuse Potential and Prescribing Considerations
intermediategabapentinmisuse potentialopioid use disorder
โ†’
9.
Trazodone Alpha-1 Blockade: Orthostatic Hypotension and Priapism
intermediatetrazodonealpha-1 antagonismorthostatic hypotension
โ†’
10.
Venlafaxine Serotonin vs Norepinephrine Dose Threshold
intermediatevenlafaxineSNRIdose-dependent
โ†’
11.
Buspirone Delayed Onset of Action and Patient Education
beginnerbuspironeonset of actionpatient education
โ†’
12.
Prazosin Titration and Blood Pressure Monitoring for PTSD Nightmares
intermediateprazosinPTSD nightmarestitration
โ†’
13.
Carbamazepine CYP3A4 Autoinduction and Drug Interactions
advancedcarbamazepineCYP3A4 inductionoral contraceptives
โ†’
14.
Fluvoxamine CYP1A2 Inhibition: Caffeine and Theophylline
advancedfluvoxamineCYP1A2caffeine
โ†’
15.
GAD-7 Score Interpretation and Treatment Monitoring
beginnerGAD-7anxiety screeningmeasurement-based care
โ†’
16.
Collaborative Care: Treatment-to-Target Adjustment
intermediatecollaborative caretreat-to-targetcaseload review
โ†’
17.
CYP3A4 Inducers and Psychiatric Drug Interactions
intermediateCYP3A4carbamazepinedrug interaction
โ†’
18.
Aripiprazole Cross-Titration: Worsening Symptoms During Switch from Full Antagonist
advancedaripiprazolepartial agonismcross-titration
โ†’
19.
Lurasidone Non-Response Troubleshooting: Inadequate Caloric Intake
intermediatelurasidoneclinical troubleshootingbioavailability
โ†’
20.
Quetiapine 25 mg: Sedative-Hypnotic, Not Antipsychotic
intermediatequetiapinedose-dependent pharmacologyclinical application
โ†’
21.
Buspirone CYP3A4 Drug Interaction with Azole Antifungal
intermediatebuspironeCYP3A4drug interaction
โ†’
22.
Venlafaxine Discontinuation Syndrome: Recognition and Management
intermediatevenlafaxinediscontinuation syndromehalf-life
โ†’
23.
Carbamazepine Autoinduction and Declining Serum Levels
advancedcarbamazepineautoinductionCYP3A4
โ†’
24.
Naloxone Precipitated Withdrawal: Mechanism and Clinical Presentation
advancednaloxoneprecipitated withdrawalmu-opioid receptor
โ†’
25.
CPT for PTSD: Assimilation vs. Over-Accommodation
intermediateCPTPTSDassimilation
โ†’
26.
DBT: Chain Analysis for Target Behaviors
intermediateDBTchain analysisborderline personality disorder
โ†’
27.
Therapeutic Alliance: Bordin's Working Alliance Model
intermediatetherapeutic allianceBordinworking alliance
โ†’
28.
Blood-Brain Barrier P-Glycoprotein and Psychotropic Drug Delivery
intermediateblood-brain barrierP-glycoproteinABCB1
โ†’
29.
Sleep Stage Neurotransmitter Regulation and Psychiatric Medication Effects
beginnersleep architectureREM sleepserotonin-acetylcholine interaction
โ†’
30.
Continuing Education and Certification Maintenance
beginnercontinuing educationANCC certificationrenewal requirements
โ†’
31.
Clozapine ANC Thresholds in Benign Ethnic Neutropenia
intermediateclozapineANC monitoring protocolbenign ethnic neutropenia
โ†’
32.
Alpha-1 Adrenergic Blockade and Orthostatic Hypotension with Antipsychotics
beginneralpha-1 blockadeorthostatic hypotensionchlorpromazine
โ†’
33.
Stimulant Side Effect Management: Appetite Suppression and Weight Loss
intermediatestimulant side effectsappetite suppressionweight loss
โ†’
34.
Trazodone Dose-Dependent Sedation vs Antidepressant Effect
intermediatetrazodoneSARIdose-dependent pharmacology
โ†’
35.
CYP2D6 Poor Metabolizer: Nortriptyline Toxicity at Standard Doses
advancedCYP2D6poor metabolizernortriptyline
โ†’
36.
Mirtazapine Dose-Dependent Sedation: The Noradrenergic Counterbalance
intermediatemirtazapineNaSSAdose-dependent sedation
โ†’
37.
Collaborative Care Model Integration for Depression
intermediatecollaborative care modelpsychiatric consultationmeasurement-based care
โ†’
38.
Using PHQ-9 and GAD-7 Thresholds for Treatment Decisions
beginnerPHQ-9GAD-7measurement-based care
โ†’
39.
Cognitive Processing Therapy for PTSD: Working with Stuck Points
intermediatecognitive processing therapyCPTPTSD
โ†’
40.
Neuroplasticity and BDNF in Antidepressant Response
intermediateneuroplasticityBDNFantidepressant
โ†’
41.
Geriatric Anticholinergic Burden and Cognitive Decline
intermediateanticholinergic burdengeriatricdelirium
โ†’
42.
Psychotherapy Integration vs. Technical Eclecticism
advancedpsychotherapy integrationtechnical eclecticismtheoretical integration
โ†’
43.
Transference and Countertransference Management
beginnercountertransferencetransferencesupervision
โ†’
44.
Malpractice Liability and Risk Reduction in Psychiatric Practice
advancedmalpracticeliabilityrisk management
โ†’
45.
Incident Reporting and Patient Safety Event Management
intermediateincident reportingpatient safetynear-miss
โ†’
46.
Just Culture Framework: Organizational Response to Reported Errors
intermediatejust culturepatient safetyincident reporting
โ†’
47.
CYP2C19 Polymorphisms and Escitalopram Dose Optimization
intermediateCYP2C19pharmacogenomicsescitalopram
โ†’
48.
Tuberoinfundibular Dopamine Pathway and Antipsychotic-Induced Hyperprolactinemia
intermediatetuberoinfundibular pathwayprolactindopamine
โ†’
49.
Histamine H1 Receptor Antagonism: Sedation and Metabolic Effects of Psychotropics
intermediatehistamineH1 receptor5-HT2C
โ†’
50.
Research Literacy: Number Needed to Treat and Number Needed to Harm
beginnerNNTNNHresearch literacy
โ†’
51.
Lithium Toxicity Risk with NSAID Interaction
intermediatelithiumdrug interactionNSAID
โ†’
52.
Carbamazepine Autoinduction and Drug Interactions
hardcarbamazepineautoinductionCYP3A4
โ†’
53.
Renal Impairment and Lithium Dose Adjustment
hardlithiumrenal impairmentnephrotoxicity
โ†’
54.
Pediatric SSRI Black Box Warning and Suicidality Monitoring
intermediatepediatricSSRIblack-box-warning
โ†’
55.
Geriatric Polypharmacy, Psychotropic Medications, and Fall Risk
intermediategeriatricpolypharmacyfall-risk
โ†’
56.
Collaborative Practice Agreement When Collaborating Physician Relocates
intermediatecollaborative practice agreementscope of practicereduced practice authority
โ†’
57.
PMHNP Scope Boundaries With Emergent Medical Complaint
intermediatescope of practicemedical emergencystandard of care
โ†’
58.
PDSA Cycle Application for Reducing Psychiatric No-Show Rates
intermediatequality improvementPDSA cycleno-show rates
โ†’
59.
Hierarchy of Evidence for Treatment-Resistant Depression Intervention
intermediateevidence-based practicehierarchy of evidencesystematic review
โ†’
60.
Clinical Supervision Model Selection for a Newly Licensed PMHNP
hardclinical supervisioncountertransferencedevelopmental model
โ†’
61.
Outcome Measurement for Tracking Depression Treatment Effectiveness
hardmeasurement-based careoutcome trackingPHQ-9
โ†’
62.
Prescriptive Authority Variation Across State Practice Acts
hardtelehealthprescriptive authoritymulti-state practice
โ†’
63.
Malpractice Standard of Care in Psychiatric Medication Management
hardmalpracticestandard of caremetabolic monitoring
โ†’
64.
Cultural Humility in Psychiatric Assessment of a Refugee Patient
hardcultural humilitycultural formulationrefugee
โ†’
65.
Documentation Standards for Initial Psychiatric Evaluation
intermediatedocumentationrisk assessmentsuicidal ideation
โ†’
66.
Telehealth Regulations and Crisis Management in Psychiatric Care
hardtelehealthcrisis managementsafety protocol
โ†’
67.
Group Therapy: Tuckman's Storming Stage
intermediategroup therapyTuckman's modelstorming stage
โ†’
68.
Psychodynamic Defense Mechanisms: Reaction Formation
intermediatedefense mechanismsreaction formationpsychodynamic
โ†’
69.
Structural Family Therapy: Enactment for Enmeshment
hardstructural family therapyenactmentenmeshment
โ†’
70.
Therapeutic Alliance Rupture and Repair
hardtherapeutic alliancerupture repairSafran and Muran
โ†’
71.
PMHNP Scope of Practice and Prescriptive Authority Limitations
intermediatescope of practiceprescriptive authorityfull practice authority
โ†’
72.
Collaborative Practice Agreement Regulatory Requirements
hardcollaborative practice agreementscope of practiceregulatory compliance
โ†’
73.
Informed Consent for Antipsychotic Metabolic Risks
intermediateinformed consentolanzapinemetabolic syndrome
โ†’
74.
Assessing Decisional Capacity for Informed Consent
hardinformed consentdecisional capacitymania
โ†’
75.
Managing Psychiatric Emergencies During Telehealth Visits
hardtelehealthpsychiatric emergencysuicidal ideation
โ†’
76.
Telehealth Prescribing of Controlled Substances Regulations
intermediatetelehealthcontrolled substanceslicensure
โ†’
77.
Interpreting Randomized Controlled Trial Results for Clinical Practice
hardevidence-based practiceresearch interpretationstatistical significance
โ†’
78.
Applying Number Needed to Treat in Psychiatric Prescribing Decisions
intermediateevidence-based practiceNNTNNH
โ†’
79.
Documentation Requirements for Involuntary Psychiatric Hold
harddocumentationinvoluntary holdmedical-legal
โ†’
80.
Documentation Standards for Malpractice Risk Mitigation
harddocumentationmalpracticeclozapine
โ†’
81.
Tarasoff Duty to Warn with Identifiable Victim
intermediateTarasoffduty to warnconfidentiality
โ†’
82.
Mandated Reporting of Elder Abuse in Psychiatric Context
intermediatemandated reportingelder abusefinancial exploitation
โ†’
83.
Evaluating SSRI Partial Response at 6 Weeks
intermediateSSRIpartial responsedose optimization
โ†’
84.
Monitoring Lithium Levels and Toxicity Recognition
hardlithiumtherapeutic drug monitoringtoxicity
โ†’
85.
Assessing Antipsychotic Response Using Rating Scales
hardschizophreniaBPRSantipsychotic response
โ†’
86.
Evaluating CBT Outcomes for Anxiety Using Standardized Measures
intermediateCBTGAD-7generalized anxiety disorder
โ†’
87.
Recognizing SSRI-Induced Apathy vs Residual Depression
hardSSRIemotional bluntingapathy syndrome
โ†’
88.
Monitoring Metabolic Syndrome with Atypical Antipsychotics
intermediatemetabolic syndromeolanzapineatypical antipsychotics
โ†’
89.
Evaluating Stimulant Response in Adult ADHD
intermediateADHDstimulantsASRS
โ†’
90.
Assessing Treatment Adherence Barriers
hardadherencelamotriginebipolar disorder
โ†’
91.
Recognizing Tardive Dyskinesia Early with AIMS Assessment
intermediatetardive dyskinesiaAIMShaloperidol
โ†’
92.
Evaluating PTSD Treatment Response with PCL-5
hardPTSDPCL-5prolonged exposure therapy
โ†’
93.
Monitoring for Suicidality During Early Antidepressant Treatment
hardsuicidalityFDA black box warningSSRI
โ†’
94.
Evaluating Psychotherapy Progress and Modality Adjustment
hardpsychotherapyIPTCBT
โ†’
95.
Evaluating Clozapine Treatment Response and Monitoring
hardclozapinetreatment-resistant schizophreniaBPRS
โ†’
96.
Assessing Benzodiazepine Taper Progress
intermediatebenzodiazepinetaperwithdrawal
โ†’
97.
Evaluating Mood Stabilizer in Bipolar Maintenance
hardvalproatebipolar Imaintenance treatment
โ†’
98.
Measuring Functional Improvement vs Symptom Reduction
intermediatefunctional impairmentPHQ-9Sheehan Disability Scale
โ†’
99.
Evaluating Cognitive Side Effects of Medications
hardtopiramatequetiapinecognitive side effects
โ†’
100.
Assessing Weight Gain Management with Antipsychotics
hardolanzapinemetabolic syndromeweight gain
โ†’
101.
Evaluating DBT Outcomes in Borderline Personality Disorder
intermediateDBTborderline personality disorderself-harm
โ†’
102.
Assessing Treatment Response in Pediatric Anxiety
intermediatepediatric anxietySCAREDmulti-informant assessment
โ†’
103.
Evaluating Smoking Cessation Pharmacotherapy Outcomes
hardvareniclinesmoking cessationschizophrenia
โ†’
104.
Monitoring Thyroid Function During Lithium Treatment
intermediatelithiumhypothyroidismTSH
โ†’
105.
Evaluating Antidepressant Augmentation Effectiveness
intermediatearipiprazoleaugmentationakathisia
โ†’
106.
Assessing Quality of Life in Chronic Mental Illness
hardquality of lifeschizophreniarecovery-oriented care
โ†’
107.
Differentiating Serotonin Syndrome from NMS
hardserotonin syndromeneuroleptic malignant syndromedrug interaction
โ†’
108.
Evaluating Geriatric Anxiety Treatment Response
hardgeriatricanxietyGAD-7
โ†’
109.
Measuring Motivational Interviewing Outcomes for SUD
hardmotivational interviewingalcohol use disorderAUDIT
โ†’
110.
Evaluating Prolactin Elevation with Antipsychotics
hardprolactinrisperidonehyperprolactinemia
โ†’
111.
Assessing Rebound Psychosis After Antipsychotic Discontinuation
hardsupersensitivity psychosisantipsychotic discontinuationolanzapine
โ†’
112.
Evaluating EMDR Response for Trauma
hardEMDRPTSDPCL-5
โ†’
113.
Monitoring Hepatic Function During Valproate Treatment
intermediatevalproatehepatotoxicityliver function tests
โ†’
114.
Evaluating Alpha-2 Agonist Response for ADHD
hardguanfacineADHDalpha-2 agonist
โ†’
115.
Assessing Treatment-Emergent Mania
hardtreatment-emergent maniabipolar disorderfluoxetine
โ†’
116.
Evaluating ECT Outcomes for Treatment-Resistant Depression
hardECTelectroconvulsive therapytreatment-resistant depression
โ†’
117.
Monitoring Renal Function During Long-Term Lithium
hardlithiumrenal functionchronic kidney disease
โ†’
118.
Evaluating IPT Response for Depression
intermediateinterpersonal therapyIPTdepression
โ†’
119.
Geriatric Benzodiazepine Deprescribing Assessment
intermediategeriatricbenzodiazepine-deprescribingfalls
โ†’
120.
DBT Crisis Survival Skills: TIPP Mechanism
hardDBTTIPP skillsdistress tolerance
โ†’
121.
Exposure and Response Prevention: Inhibitory Learning
hardERPOCDinhibitory learning
โ†’
122.
Evaluating Treatment Response in First-Episode Psychosis
hardfirst-episode psychosisrisperidonePANSS
โ†’
123.
Evaluating SNRI Efficacy for Comorbid Pain and Depression
hardduloxetineSNRIfibromyalgia
โ†’
124.
Evaluating for Medication-Induced QTc Prolongation
hardQTc prolongationziprasidoneondansetron
โ†’
125.
Evaluating Prazosin Efficacy for Trauma-Related Nightmares
hardprazosinPTSDnightmares
โ†’
126.
Evaluating Treatment Response in Social Anxiety Disorder
hardsocial anxiety disordersertralineLSAS
โ†’
127.
Evaluating Methylphenidate vs Amphetamine Response
hardADHDmethylphenidateamphetamine
โ†’
128.
Evaluating Strategies for Medication-Induced Weight Gain
hardolanzapineweight gainmetabolic syndrome
โ†’
129.
Evaluating Treatment Adherence with LAI Antipsychotics
hardLAIaripiprazole lauroxiladherence
โ†’
130.
Evaluating for Emerging Diabetes During Antipsychotic Treatment
harddiabetesquetiapinemetabolic monitoring
โ†’
131.
Evaluating Buspirone Augmentation for Anxiety
hardbuspironeaugmentationgeneralized anxiety disorder
โ†’
132.
Evaluating Gabapentinoid Efficacy for Neuropathic Pain in Psychiatric Patients
hardpregabalinneuropathic painrenal impairment
โ†’
133.
Evaluating Treatment Response in Resistant Insomnia
moderateinsomniaCBT-Itrazodone
โ†’
134.
Fluvoxamine-Clozapine CYP1A2 Inhibition
hardfluvoxamineclozapineCYP1A2
โ†’
135.
Lithium-NSAID Renal Interaction Mechanism
hardlithiumNSAIDibuprofen
โ†’
136.
Serotonin Syndrome Risk with Tramadol and SSRI Combination
hardtramadolSSRIsertraline
โ†’
137.
Methadone QTc Prolongation and CYP3A4 Inhibitor Risk
hardmethadoneQTc prolongationCYP3A4
โ†’
138.
Grapefruit Juice CYP3A4 Interaction with Psychiatric Medications
hardgrapefruit juicebuspironeCYP3A4
โ†’
139.
Warfarin-SSRI Bleeding Risk Interaction
hardwarfarinfluoxetineSSRI
โ†’
140.
Smoking Cessation Effect on Clozapine Metabolism
hardclozapinesmoking cessationCYP1A2
โ†’
141.
Levothyroxine Absorption and Psychiatric Medication Timing
intermediatelevothyroxinecalciumiron
โ†’
142.
Measurement-Based Care Implementation Using Standardized Outcome Tracking
hardmeasurement-based carePHQ-9treatment response
โ†’
143.
Psychiatric Consultation-Liaison Role in Postoperative Delirium Assessment
hardconsultation-liaisondeliriumpostoperative
โ†’
144.
Risk Management Documentation in Outpatient Psychiatric Practice
hardrisk managementsuicide assessmentdocumentation
โ†’
145.
Patient Safety and Medication Error Prevention Strategies
hardpatient safetymedication errorssystems-based practice
โ†’
146.
Reflective Practice and Countertransference in Clinical Supervision
hardreflective practiceclinical supervisioncountertransference
โ†’
147.
Concussion and Psychiatric Sequelae in Athletes
hardconcussionsports-psychiatrypost-concussion-syndrome
โ†’
148.
Evaluating Response to CBT Augmentation for Treatment-Resistant OCD
hardOCDexposure and response preventionY-BOCS
โ†’
149.
Evaluating Anticonvulsant Mood Stabilizer Blood Levels
hardvalproic acidtherapeutic drug monitoringketogenic diet
โ†’
150.
Evaluating the Effect of Pregnancy on Psychiatric Medication Metabolism
hardpregnancysertralinepharmacokinetics
โ†’
151.
Evaluating Response to Integrated Dual-Diagnosis Treatment
harddual diagnosisbipolar II disorderalcohol use disorder
โ†’
152.
Evaluating for Antidepressant Poop-Out (Tachyphylaxis)
hardtachyphylaxisantidepressant poop-outescitalopram
โ†’
153.
Evaluating Pediatric SSRI Response Using Validated Measures
hardpediatric depressionfluoxetineCDRS-R
โ†’
154.
Evaluating Treatment Response in Panic Disorder
hardpanic disorderagoraphobiaPDSS
โ†’
155.
Evaluating Medication Adherence with Urine Drug Testing
hardmedication adherenceurine drug testingschizophrenia
โ†’
156.
Evaluating Cognitive Effects of Benzodiazepines in Elderly
hardbenzodiazepineslorazepamelderly
โ†’
157.
Evaluating Treatment Response in Insomnia Using Sleep Diary
hardinsomniaCBT-Isleep diary
โ†’
158.
Evaluating Impact of Comorbid Medical Conditions on Psychiatric Treatment
hardchronic kidney diseasevenlafaxinerenal clearance
โ†’
159.
Evaluating Family Therapy Outcomes in Adolescent Depression
hardadolescent depressionattachment-based family therapyfamily therapy
โ†’
160.
Evaluating Polypharmacy Reduction Outcomes
hardpolypharmacydeprescribingakathisia
โ†’
161.
Evaluating Long-Term Antidepressant Continuation Criteria
hardantidepressant maintenancerecurrent depressioncontinuation criteria
โ†’
162.
Evaluating Treatment Response in ARFID
moderateARFIDfeeding disordertreatment response
โ†’
163.
Antipsychotic Metabolic Syndrome Monitoring
intermediateolanzapinemetabolic syndromeantipsychotic
โ†’

Other AANPCB domains

๐Ÿ”Ž Assess (33%)๐Ÿงฉ Diagnose (21%)๐Ÿ“ Plan (26%)

Want to understand the full AANPCB blueprint? Read the complete AANPCB exam guide โ†’

โ† AANPCB Board Prep